Chinese firm Shanghai Fosun Pharmaceutical has extended the termination date for its $1.3bn proposal to acquire approximately 86.08% stake in Indian sterile injectables maker Gland Pharma on 26 September.

Fosun said that the acquisition is still subject to the review and approval of the Cabinet Committee on Economic Affairs (CCEA) of India, which is yet to take any decision on the closure of the deal, reported The Economic Times.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In a Hong Kong stock exchange filing, Fosun said: “The approvals of the relevant PRC authorities in respect of the acquisition have been obtained and the US antitrust filings and the Indian anti-trust filings have been completed.”

The company added: “In addition, the acquisition was reviewed by the Indian Foreign Investment Promotion Board, which has been recommended to the Cabinet Committee on Economic Affairs of India for further review.”

"The approvals of the relevant PRC authorities in respect of the acquisition have been obtained and the US antitrust filings and the Indian anti-trust filings have been completed."

Last July, Fosun Pharma, along with private equity firm KKR, announced the proposed acquisition of the controlling interest in Gland.

See Also:

KKR owns 36% share in the Indian pharmaceutical company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, reports emerged that the deal has been stopped due to the growing India-China border tensions.

Gland Pharma vice-chairman and managing director Ravi Penmetsa was quoted by the Press Trust of India (PTI) as saying: “We have not had any official communication from any of the governmental departments so far.”

Based in Hyderabad, India, Gland Pharma claims to have pioneered Heparin technology in the country and has a position in the Glycosaminoglycans range of molecules that are useful for some cancer treatments.